BACKGROUND: Conventional therapeutic approaches to treat advanced renal cell carcinoma (RCC) are of limited benefit. Receptor tyrosine kinase inhibitors (RTKI) may open up novel treatment options. In the present study, the effects of the RTKI AEE788 on the growth and adhesion capacity of RCC cell lines were evaluated in vitro. MATERIALS AND METHODS: RCC cells were treated with AEE788, and alterations of tumor growth and tumor cell interaction with vascular endothelium or extracellular matrix proteins were analyzed. Furthermore, the addition of interferon alpha (IFNalpha) was investigated to see whether it may enhance the anti-tumoral potential of AEE788. RESULTS: AEE788 significantly blocked RCC cell growth and adhesion. Analysis of alpha- and beta-integrins revealed distinct alterations of the receptor expression profile and downregulation of integrin-dependent signaling. Growth-blocking effects were further enhanced when the AEE788-IFNalpha combination protocol was applied. In addition, downregulation of integrin-dependent signaling was more intense in the presence of a combination of AEE788 and IFNalpha than with AEE788 monotherapy. CONCLUSIONS: AEE788 exerts significant anti-tumoral properties, particularly when combined with IFNalpha. AEE788 may therefore be an encouraging compound to treat advanced RCC.
BACKGROUND: Conventional therapeutic approaches to treat advanced renal cell carcinoma (RCC) are of limited benefit. Receptor tyrosine kinase inhibitors (RTKI) may open up novel treatment options. In the present study, the effects of the RTKI AEE788 on the growth and adhesion capacity of RCC cell lines were evaluated in vitro. MATERIALS AND METHODS:RCC cells were treated with AEE788, and alterations of tumor growth and tumor cell interaction with vascular endothelium or extracellular matrix proteins were analyzed. Furthermore, the addition of interferon alpha (IFNalpha) was investigated to see whether it may enhance the anti-tumoral potential of AEE788. RESULTS:AEE788 significantly blocked RCC cell growth and adhesion. Analysis of alpha- and beta-integrins revealed distinct alterations of the receptor expression profile and downregulation of integrin-dependent signaling. Growth-blocking effects were further enhanced when the AEE788-IFNalpha combination protocol was applied. In addition, downregulation of integrin-dependent signaling was more intense in the presence of a combination of AEE788 and IFNalpha than with AEE788 monotherapy. CONCLUSIONS:AEE788 exerts significant anti-tumoral properties, particularly when combined with IFNalpha. AEE788 may therefore be an encouraging compound to treat advanced RCC.
Authors: Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Isabelle Soerjomataram; Jan Willem Coebergh; Marieke W J Louwman; Otto Visser; Flora E van Leeuwen Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Wei-Zhong Wu; Hui-Chuan Sun; Yue-Fang Shen; Jie Chen; Lu Wang; Zhao-You Tang; George Iliakis; Kang-Da Liu Journal: J Cancer Res Clin Oncol Date: 2004-12-11 Impact factor: 4.553
Authors: Surinder Kaur; Antonella Sassano; Blazej Dolniak; Sonali Joshi; Beata Majchrzak-Kita; Darren P Baker; Nissim Hay; Eleanor N Fish; Leonidas C Platanias Journal: Proc Natl Acad Sci U S A Date: 2008-03-13 Impact factor: 11.205
Authors: Jon Jones; Dana Marian; Eva Weich; Tobias Engl; Steffen Wedel; Borna Relja; Dietger Jonas; Roman A Blaheta Journal: Exp Cell Res Date: 2007-07-10 Impact factor: 3.905
Authors: E Juengel; M Bhasin; T Libermann; S Barth; M Michaelis; J Cinatl; J Jones; L Hudak; D Jonas; R A Blaheta Journal: World J Urol Date: 2010-07-17 Impact factor: 4.226